UK fines Pfizer and Flynn Pharma record £84m for abuse of position

Pfizer and Flynn Pharma were fined a record amount for abusing their dominant position in the UK by charging unfair prices for unbranded versions of the Epanutin anti-epilepsy drug.

The UK’s Competition and Markets Authority fined Pfizer £84.2m (€99.7m) and Flynn Pharma £5.2m after they rose prices by as much as 2,600% in September 2012, the regulator has said.

The price increases occurred after Pfizer transferred distribution rights to Flynn, which sold the medicine by its generic name, phenytoin sodium.